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Tau plays an important pathological role in a group of neurodegenerative diseases
called tauopathies, including Alzheimer’s disease, Pick’s disease, chronic traumatic
encephalopathy and corticobasal degeneration. In each disease, tau self-assembles
abnormally to form filaments that deposit in the brain. Tau is a natively unfolded protein
that can adopt distinct structures in different pathological disorders. Cryo-electron
microscopy has recently provided a series of structures for the core of the filaments
purified from brain tissue from patients with different tauopathies and revealed that
they share a common core region, while differing in their specific conformation. This
structurally resolvable part of the core is contained within a proteolytically stable core
region from the repeat domain initially isolated from AD tau filaments. Tau has recently
become an important target for therapy. Recent work has suggested that the prevention
of tau self-assembly may be effective in slowing the progression of Alzheimer’s disease
and other tauopathies. Here we review the work that explores the importance of tau
filament structures and tau self-assembly mechanisms, as well as examining model
systems that permit the exploration of the mode of action of potential inhibitors.
Keywords: tau, tauopathies, Alzheimer’s disease, tau aggregation inhibitors, in vitro models, self-assembly,
filaments
INTRODUCTION
Newly synthesized and unfolded proteins must undergo a carefully controlled folding process
to produce their specific biologically active conformation, known as the native state. This is a
specific 3D structure required for correct protein function and is encoded in the amino acid
sequence (1). This folding process can be thought of as following an energy landscape whereby
the unfolded polypeptide folds to form the native state, the most thermodynamically stable
configuration for the polypeptide (2). The unfolded proteins at the top of the landscape are
initially driven by hydrophobic collapse to form secondary structure and further intramolecular
contacts, such as covalent bonds and hydrogen bonds, help the proteins reach their native state
(3, 4). Alternatively, proteins can form misfolded intermediates, which can go on to generate a
pathological conformation leading to the formation of amyloid fibrils. However, multiple diseases
are associated with stable aggregates that have formed as a result of the assembly of misfolded
proteins and dysfunctions in the protective mechanisms, such as the molecular chaperones (1, 2, 5).
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Contrary to the native state, where hydrophobic residues are
protected, misfolded proteins have exposed hydrophobic
residues. This facilitates the formation of hydrophobic
interactions between misfolded proteins and drives the self-
assembly of proteins into protein amyloid (6). Amyloid fibrils are
composed of assembled peptides formed of β-sheets with a typical
cross-β structure, which is common for all amyloid, regardless
of the amino acid sequence and native structure of the precursor
protein (7). The conversion of soluble, monomeric protein
into amyloid fibrils includes the production of partially folded
intermediates, which have become a focus for understanding
pathogenesis of disease in recent years (8–11). These include
dimers, trimers, tetramers, oligomers, and protofilaments
(12–15). Mature amyloid fibrils are made of several individual
protofilaments (16). The accumulation of amyloid fibrils,
and their related intermediates, are strongly associated with
cellular dysfunction and are common pathological hallmarks for
neurodegenerative diseases, such as Alzheimer’s disease (AD),
Parkinson’s disease and Huntington’s disease.
Each neurodegenerative disease has its own disease-specific
protein that forms disease-specific amyloid fibrils. Nevertheless,
there is a group of neurodegenerative diseases, known as
tauopathies, that are characterized by the presence of amyloid
fibrils consisting entirely of self-assembled tau protein. Filaments
that accumulate in the various tauopathies differ in the specific
fibril structure as a result of tau aggregation, but this highlights
an opportunity where an understanding of tau self-assembly
in one tauopathy, may benefit our research in investigating
another tauopathy.
TAU PROTEIN IN DISEASE
Physiological Expression and Function
Human tau protein is encoded by the MAPT gene located on
chromosome 17 and is expressed in the central nervous system
as a family of six isoforms. These isoforms are the product of
alternative mRNA splicing of transcripts from MAPT, resulting
in proteins of varying amino acid lengths from 352 to 441.
They differ by the presence of zero, one or two N-terminal
inserts encoded by exons 2 and 3 (0N, 1N, 2N), and the
inclusion or absence of the second 31 amino acid microtubule-
binding repeat (R2) in the C-terminal half (encoded by exon
10). Inclusion of exon 10 results in the production of three
tau isoforms each having four repeats (4R) and the absence of
Abbreviations: AD, Alzheimer’s disease; 4R, four-repeats; 3R, three-repeats;
FTDP-17, frontotemporal dementia with parkinsonism-linked to chromosome 17;
Aβ, amyloid beta; FTD, frontotemporal dementia; PiD, Pick’s disease; CTE, chronic
traumatic encephalopathy; CBD, corticobasal degeneration; PART, primary age-
related tauopathy; PSP, progressive supranuclear palsy; AGD, argyrophilic grain
disease; cryo-EM, cryo-electron microscopy; NFT, neurofibrillary tangle; PHF,
paired helical filament; SF, straight filament; mAb, monoclonal antibody; bvFTD,
behavioral-variant frontotemporal dementia; NPF, narrow Pick filament; WPF,
wide Pick filament; PTM, post-translational modification; MTBR, microtubule-
binding region; TAI, tau aggregation inhibitor; MT, methylthioninium; LMT,
leuco-methylthioninium; MTC, methylthioninium chloride; LMTM, leuco-
methylthioninium bis(hydromethanesulfonate).
exon 10 produces three isoforms having only three repeats (3R)
(Figure 1) (23, 24).
Tau is a family of microtubule-associated proteins responsible
for promoting and stabilizing the microtubule network (25,
26). These functions are facilitated by the microtubule-binding
domain in the C-terminal domain, with 4R isoforms shown
to be better at promoting microtubule assembly and binding
to microtubules than the 3R isoforms (27). Microtubules are
essential for a range of cellular processes for the maintenance
of neuronal morphology, such as intracellular transport of
organelles, cell division and signal transduction (28). It is
important to note that the different isoformsmay be differentially
localized depending on the developmental stages, tissues, cell
lines, brain regions and intracellular compartments (29–34). For
instance, in the murine brain, 1N tau isoforms are overexpressed
in the pituitary gland, compared to the cortex or hippocampus
and under-expressed in the olfactory bulb. The 2N isoforms are
enriched in the cerebellum compared to any other brain region,
but are under-expressed in the olfactory bulb; the 0N isoforms
are the predominantly expressed isoforms in the olfactory
bulb and cortex (34). Intracellularly, in the murine brain, 1N
isoforms predominate in the nuclear fraction and 0N isoforms
predominate in the cell body/axons (34). In human immortalized
cells, like SH-SY5Y neuroblastoma cells, tau may localize to
the nucleus or cytoplasm depending on whether the cells are
differentiated or not (35). Moreover, it has been shown that the
3R isoform of tau is preferentially localized to the nucleolus (29).
Tau has been observed to bind nucleic acids, suggesting the
involvement of tau in chromatin remodeling. This interaction
with DNA indicates that tau proteins may play a role in
protection against reactive oxygen species (36, 37), ribosome
stability and miRNA activity (38). It has also been shown that
tau plays a role in nucleolar transcription and participates in
the nucleolar stress response (39, 40). These roles seem to be
important in the pathogenesis of tauopathies. For example, tau
pathology has been shown to impair nucleocytoplasmic transport
in AD and frontotemporal dementia (41, 42), induce nuclear
envelope invagination in AD (43, 44), induce neurodegeneration
through global chromatin relaxation (45), and transposable
element dysregulation in AD (46). These studies emphasize the
importance of a nuclear role for tau in tauopathies.
Tauopathies
Tauopathies are clinically, biochemically and morphologically
heterogenous neurodegenerative diseases characterized by the
deposition of abnormal aggregates of tau in the brain (47).
In each tauopathy, tau self-assembles via the repeat domains
to form a disease-specific conformation, which associates to
form disease-specific amyloid fibrils. It is widely recognized
that the accumulated tau pathology seen in tauopathies is
directly associated with cognitive decline and clinical dementia
in patients suffering with these diseases (48–56). The importance
of tau in neurodegeneration was emphasized when it was
discovered that dominantly inherited mutations in MAPT
cause frontotemporal dementia with parkinsonism-linked to
chromosome 17 (FTDP-17) (57–59). Unlike AD, FTDP-17 is not
characterized by the presence of amyloid β (Aβ) peptide plaques
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FIGURE 1 | Full-length tau (isoform 2N4R) containing two N-terminal inserts (N1 and N2), two proline-rich regions (P1 and P2) and four microtubule-binding repeats
(R1–R4). Antibody AT8 recognizes an epitope dependent on phosphorylation at Ser201 and Thr205. The 6 residue PHF (306–311) and PHF6* (17–22) fragments are
from repeat regions R3 and R2, respectively.
but patients exhibit cognitive decline. Pathologically aggregated
tau is therefore sufficient, in the absence of Aβ to result in
neurodegeneration and dementia in the absence of Aβ (60).
Tauopathies include AD, frontotemporal dementia (FTD:
which includes Pick’s disease (PiD) as a sub-type), chronic
traumatic encephalopathy (CTE), corticobasal degeneration
(CBD), primary age-related tauopathy (PART), progressive
supranuclear palsy (PSP), and argyrophilic grain disease (AGD).
Table 1 outlines key features of the tau aggregates associated
with different tauopathies. They can be classified into primary
or secondary depending on whether tau aggregates represent the
sole molecular lesion, or if the disease is associated with other
pathological features, such as Aβ plaques in AD (73). Tauopathies
can be further distinguished by the tau isoforms present in their
filaments, with AD and CTE comprising all six isoforms (3R and
4R), CBD, PSP, and AGD only comprising only 4R isoforms, and
PiD only containing 3R isoforms (67).
Characteristics of Tau Aggregates
For each tauopathy, revealing the unique molecular signatures
for the disease-specific fibrils is a vital step toward understanding
key assembly mechanisms and interactions. Recent cryo-electron
microscopy (cryo-EM) studies have revealed the atomic structure
of the tau fibrils associated with AD, PiD, CTE, and CBD. In this
section we explore the similarities and differences between the
molecular structures of these aggregates (Figure 2).
Alzheimer’s Disease (AD)
AD is the leading cause of dementia and is characterized
by the presence of extracellular amyloid plaques, composed
of Aβ peptide, and intracellular neurofibrillary tangles
(NFTs), composed of tau (74–76). The accumulation of these
pathological hallmarks causes progressive neurodegeneration
in the neocortex, hippocampus and cingulate gyrus, leading to
cognitive decline (77).
NFTs are composed of two types of fibrils: paired helical
filaments (PHFs) and straight filaments (SFs) (49, 78–80).
In AD, PHFs predominate (90%), whereas filaments in PiD
are predominately SFs (95%). Initial proteolytic cleavage and
antibody labeling studies established that PHFs isolated from
AD brain tissue comprise of a core that is resistant to a
broad-spectrum exo-protease (Pronase), which is covered with
a Pronase-sensitive “fuzzy coat” (74, 81). Pronase treatment
removes the “fuzzy coat” leaving the intact PHF-core, which
reacts with monoclonal antibody 423 (mAb 423) that recognizes
tau truncated at E391 (82). These experiments confirmed that
tau is the major structural component of the PHF core (83–85).
Negative-stain electron microscopy further revealed that the core
comprises of a double helical stack of C-shaped subunits, with
the N- and C-terminal regions projecting away from the core in
a disordered manner to form the “fuzzy coat” (86).
In a recent cryo-EM study, Fitzpatrick and colleagues solved
the structure of the shared common structural core of PHFs
and SFs, consisting of residues V306—F378, indicating the
inclusion of R3 and R4 repeats plus an additional 10 amino
acids at the C-terminus (62). This allows for the incorporation
of all six tau isoforms. Labeling with an R2-specific epitope
antibody (anti-4R, raised against V275-C291 of R2) was used to
suggest the absence of R2 from the core, although R2 sequences
were identified in core PHF characterized biochemically (84).
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Paired helical filaments (PHFs):
longitudinal spacing between
crossovers of 65–85 nm and a
width of 7 nm at the narrowest parts
and 15 nm at the widest section
Straight filaments (SFs): 10 nm wide
with crossovers distances ranging
from 70–90 nm
Alzheimer fold: Identified by
Fitzpatrick and colleagues,
consisting of residues 306-378 of
3R and 4R tau (all R3 and R4
repeats, and 10 amino acids after






Primary Pick bodies Narrow Pick filaments (NPFs):
helical twist with a crossover
distance of ∼100 nm and a width of
5–15 nm
Wide Pick filaments (WPFs): helical
twist with a crossover distance of
∼100 nm and a width of 5–30 nm
Pick fold: Identified by Falcon and
colleagues, consisting of residues
254–378 of 3R tau (C-terminal part
of R1 repeat, all R3 and 4R repeats,
and 10 amino acids after 4R). Nine





Primary NFTs and glial tangles
(GTs)
CTE type I filaments: Predominant
helical filaments widths of 20–25 nm
and crossover spacing of
65–80 nm.
CTE type II filaments: pronounced
helical twists with widths of
15–30 nm.
Paired helical filaments (PHFs)
CTE fold: Identified by Falcon and
colleagues, consisting of residues
274–379 for 3R tau, 305–379 for
4R tau. Eight β-strands adopting a
C-shaped architecture in a more
open configuration than the





Primary NFTs, coiled bodies,
argyrophilic threads
and astrocytic plaques
Type I/narrow filaments: Consist of
a single protofilament with a helical
twist with a crossover distance
∼100 nm, width of 8 nm (min) and
13 nm (max)
Type II/wide filaments: Consist of a
pair of identical protofilament of type
I, with a helical twist with crossover
distance of ∼140 nm and a width of
8 nm (min) and 26 nm (max)
CBD Fold: Identified by Zhang and
colleagues, consisting of residues
274–380 of 4R tau (last residue of
R1 repeat, all R2, R3, and R4
repeats, and 12 amino acids after
R4 repeat). Eleven β-strands form a




with parkinsonism linked to
chromosome 17 (FTDP-17)
(67)
Primary Massive neuronal and
glial tau deposits
Tau protofilament is an 11–12 nm
diameter tubule











13–14 nm diameter straight tubules,
two pair along longitudinal axes,
show periodic narrowing at
220–400 nm and diameters of
22–24 nm (max) and 11–12 nm
(min)
Not yet resolved 4R
Primary age-related
tauopathy (PART) (69)
Primary NFTs Tau fibrils display a typical PHF
morphology








9–18 nm diameter straight filaments
or 25 nm diameter tubules
Not yet resolved 4R
The core structure is an in-register parallel β-sheet formed
by a β-bend and a β-helix motif linked by β-strands, which
forms the previously identified C-shape (termed Alzheimer’s
fold) (Figure 2). In addition, these findings have confirmed the
presence of the hexapeptide, 306VQIVYK311 (PHF6) in the core
of AD filaments, located in the N-terminal part of the cross-β
structure and that packs through a heterotypic, non-staggered
interface with the opposing residues 373THKLTF378 (Figure 2).
PHF6 has been considered essential for tau self-assembly (87, 88).
PHFs and SFs are formed from two identical protofilaments
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FIGURE 2 | Cryo-electron microscopy structures of ex-vivo filaments from AD (6hre, 6hrf), PiD (6gx5), CTE (6nwq, 6nwp), and CBD (6tjx) depicting a single layer slice
through the filament with a view down the filament axis using cartoon ribbons in Pymol (61). Key regions are highlighted in color as stick representations. Structures
have been arranged to highlight comparisons of key region positions. The primary sequence is shown below, highlighted in the same colors for each region. Cys322 is
highlighted in yellow as a stick representation. Pink box signifies AD PHF-core dGAE sequence 297–391. Gray outline signifies region resolved by CryoEM for AD PHF.
Blue 342–349 is found at the β-helical bend in AD PHF and SF as well as CTE-I and -II, but is found at the dimer interface for CBD-I and -II and at a kink in PiD. Red
332–336 is found at the dimer interface for AD PHF and for CTE-II interface, while purple 323–329 is found at the dimer interface for CTE-I. Orange 306–311 (PHF6)
interdigitates with cyan 373–378 across the sheets between the N- and C- terminal ends of the core in AD PHF, AD SF and CTE-I and II. However, in PiD and CBD-I
and II, 306–311 interdigitates with 336–340. In the recently solved CBD structures, black 275–280 (PHF6*) interdigitates with cyan 373–378. Green is found at the
N-terminus of PiD. Pink arrow points to the absence of R2 in PiD narrow filament structure. AD: (62, 63) PiD (64); CTE: (65); CBD: (66).
that differ in the way they are packed, displaying ultrastructural
polymorphism (62); PHF protofilaments are paired base-to-base,
whereas SF protofilaments are paired back-to-base (Figure 2).
Pick’s Disease (PiD)
PiD, an uncommon subtype of FTD, is a neurodegenerative
disorder characterized by the presence of tau-positive filaments,
contained in lesions originally described as Pick’s bodies
found throughout the limbic and neocortical regions. PiD
presents clinically with a combination of aphasia and behavioral
abnormalities. The most prevalent FTD syndrome is behavioral-
variant FTD (bvFTD) and is characterized initially by personality
changes and impairment in judgement in the absence of
memory impairment. The broader class of frontotemporal lobar
degeneration disorders includes primary progressive aphasia,
corticobasal syndrome, and a Parkinsonian syndrome (89).
Cryo-EM distinguished narrow and wide Pick filaments
(NPFs and WPFs, respectively), with NPFs being the primary
filament observed (64). NFPs are composed of a single
protofilament with a Pick tau filament fold (termed the Pick
fold) (Figure 2). Whereas, the WPFs are seen to be two NPF
protofilaments interacting at their distal tips. As in AD, these
filaments are composed of a Pronase-resistant core surrounded
by a “fuzzy coat” of disordered N- and C-terminal projections,
which are removed after Pronase treatment. The Pick fold
encompasses the core region, which consists of residues K254—
F378 of 3R tau, including the C-terminal part of R1, all of
R3 and R4, and 10 amino acids after R4. This confirmed the
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selective incorporation of 3R tau only in Pick body filaments.
The core structure consists of 9 β-strands arranged into four
cross-β packing stacks and connected by turns and arcs, which
creates an elongated structure that is distinct from the C-shaped
sub-structure of protofilaments seen in AD (Figure 2) (64).
Chronic Traumatic Encephalopathy (CTE)
CTE is a neurodegenerative tauopathy associated with repeated
head trauma, identified in former participants of contact
sports (boxing, American football, and soccer), ex-military
personnel, and victims of severe physical abuse (90–93). CTE
is characterized by an abundance of hyperphosphorylated tau
protein within NFTs and glial tangles, with tau aggregates
forming in cortical layers II and III (94–97).
Falcon and colleagues found two novel filament structures
in CTE brain tissue (termed CTE type I and CTE type II
filaments), which are ultrastructural polymorphs that share
protofilaments, but with a different protofilament interface
(Figure 2). In addition to these, they found a small fraction
of filaments that were identical to AD PHFs (65). With the
use of antibody labeling, it has been shown that all six tau
isoforms in a hyperphosphorylated state are incorporated into the
protofilaments similar to AD (76). The core of the protofilaments
consists of residues K274-R379 of R3 tau and S305-R379 of
R4 tau to form a C-shaped conformation, termed the CTE
fold, which resembles the Alzheimer’s fold (Figure 2). However,
due to a different β-strand packing in the β-helix motif and a
hydrophobic cavity, absent in AD filaments, CTE protofilaments
have a more open C-shape conformation than seen in AD
(see Figure 2). The hydrophobic cavity contains an additional
density that is not connected to the density of the tau molecules,
suggesting it is not covalently linked and does not appear to
be a post-translational modification (PTM) (65). The authors
suggest candidatemoleculesmight be non-polar sterols and sterol
derivatives, or fatty acids. The hydrophobic cavity containing
the additional density has highlighted the structural differences
seen in tauopathy filaments, as well as identifying a potentially
important step in the pathogenesis of CTE. With the presence of
tau inclusions around blood vessels in CTE, the authors suggest
the additional density represents cofactors that may be involved
in the initiation of tau aggregation in CTE, which may enter the
brain after head trauma or other mechanisms (65).
Corticobasal Degeneration (CBD)
CBD is a neurodegenerative tauopathy characterized by neuronal
and glial deposits of hyperphosphorylated tau throughout the
somatosensory, premotor, supplementary motor cortices, basal
ganglia and brainstem (98). Patients present with motor and
cognitive decline, including corticobasal syndrome, Richardson
syndrome, and Alzheimer’s-like dementia (99).
Zhang and colleagues have revealed two unique filaments
that comprise the neuronal and glial deposits of CBD, termed
type I (narrow) and type II (wide) CBD filaments (66). Type
I CBD filaments are composed of a single protofilament with
a helical twist that adopts a previously unknown four-layered
fold, while type II CBD filaments consist of a pair of identical
protofilaments of type I, exhibiting helical twists and related by
mirror symmetry. Type I and II filaments contain a common
protofilament, consisting of a core structure composed of
residues K274-E380, which covers the last residue of R1, all
of R2-R4, and 12 amino acids after R4. The core consists of
11 β-strands that are connected by turns and arcs to form a
previously unknown four-layered structure, termed the CBD fold
(Figure 2). Like the CTE fold, the CBD cryo-EM map contains
additional density that the authors suggest may be composed
of non-proteinaceous, polyanionic molecules. Unlike CTE, the
additional density in CBD is contained in a hydrophilic cavity.
The authors have suggested that these molecules may enter the
brain from the periphery and aid the formation of the CBD fold
and filaments, as in the hypothesis of Falcon and colleagues for
CTE filament assembly (65, 66).
Identifying the different conformations of tau folds in these
different diseases has been a pivotal step in our understanding
of tau aggregates and the important interactions involved in tau
self-assembly. These structures have demonstrated the ability of
tau to form distinct molecular conformations that could account
for the structural diversity of tau aggregates within the different
tauopathies. The structural differences seen in tau filaments from
AD and CTE indicate that tau isoform composition is not the sole
determinant of conformation, and that the distinct tau structures
observed are the result of precise disease-specific processes (62,
65, 100).
AD is the most prominent tauopathy, thought to account for
around 60–70% cases of dementia worldwide and is expected
to affect 100 million patients by 2050 (101). The remainder of
this review will focus on tau assembly observed in AD and
the use of in vitro models of tau aggregation. However, it is
important to consider the potential significance and relevance of
tau self-assembly findings in AD research for other tauopathies.
Tau Self-Assembly in AD
Full-length recombinant tau shows very little intrinsic tendency
to aggregate in vitro, due to its hydrophilic nature and absence
of PTMs that may promote aggregation (102, 103). Our
understanding of tau aggregation has come mostly from in
vitro studies using tau models, in which exogenous additives
are required to initiate tau aggregation, or fragments of tau
that can spontaneously aggregate. Additives include polyanionic
factors, such as heparin or RNA (104–106), and arachidonic
acid (107). Early studies demonstrated that pathological tau-
tau binding through the repeat domain instigates the formation
of the proteolytically stable structure of the PHF core (108,
109). This process exhibits a “prion-like” characteristic, whereby
aggregation of tau seems to be auto-catalytic and self-propagating
(110). Tau protein undergoes repeated binding and proteolytic
digestion cycles, leading to the accumulation of a PHF-core tau
fragment at the expense of native tau. The accumulating fragment
lacks the N-terminus and terminates at the C-terminus at E391
(108) (Figure 3). Key regions that drive filament formation are
thought to be the hexapeptides 306VQIVYK311 (PHF6) and
275VQIINK280 (PHF6∗), (highlighted in Figure 1) (87, 88). PHF6
has been suggested as essential for tau self-assembly (87, 111)
and cryo-EM has revealed its presence in the core region, where
it packs through a heterotypic, non-staggered interface with
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FIGURE 3 | In vitro tau aggregation by autocatalytic propagation. Native tau misfolding (yellow) is triggered by unknown cellular components (gray surface) initiating a
structural conversion. This misfolded tau (yellow) acts as a seed that binds full-length, native tau (cyan) and converts the repeat domain into a proteolytically stable
conformational replicate (cyan). This process repeats (white), leading to formation of elongated fibrils (6 layers shown). Excess regions of tau outside the core (fuzzy
coat) are removed prior to or during conversion or after assembly (exact details unknown). The structure of a single protofilament is shown for simplicity, although
dimerization is an important step for AD PHF formation. Single chain layers are shown in yellow, cyan and white. The morphological detail is created using a single
layer and chain of 6hre.pdb as a template and Pymol was used to prepare a surface representation (61).
373THKLTF378 (62) (Figure 2). However, it has been suggested
that PHF6∗ is a more powerful driver of 4R tau aggregation and
a superior target for inhibiting assembly of 4R tau (112).
It is not known what initiates the self-assembly of tau protein
in vivo. Lipofuscin deposits have been suggested as a substrate
thatmight capture tau and induce a stable conformational change
in the protein. Lipofuscin is composed of undigested products of
mitochondrial turnover as a result of a dysfunctional endosomal-
lysosomal pathway (109, 113, 114). Alternatively, tau on its own,
either as oligomers or short fibrils, can initiate or seed the
recruitment of monomers in tau self-assembly (115, 116). This
process is discussed later in this review.
The events or factors that initiate the process of autocatalytic
aggregation of tau protein remain unclear. No differences in the
primary amino acid sequence have been identified in the tau
fragment extracted from PHF preparations, which indicates that
any pathological processing of tau associated with PHF assembly
must be induced by conformational or post-translational changes
in the protein (75, 117, 118).
Tau exists as a natively unfolded protein and is subject to
many PTMs, such as phosphorylation and truncation, which
affect its biological function. Nonetheless, aberrant PTMs may be
associated with preventing tau function by inhibiting tau-tubulin
binding, while promoting pathological tau self-assembly (119–
122). Understanding these PTMs is extremely important when
studying the key initiation mechanism of tau self-assembly and
are therefore important when considering reliable tau models.
Phosphorylation
Tau is a phosphoprotein and exists in a dynamic equilibrium
between a microtubule-bound and -free state, controlled by the
extent of its phosphorylation. Tau contains up to 85 potential
phosphorylation sites, with the main kinases responsible for tau
phosphorylation identified as GSK3β, CDK2, CDK5, CaMKII,
and PKA. The major phosphatases, that dephosphorylate tau
include PP2A, PP2B, PP2C, with PP2A considered the main
phosphatase (123–125).
PHFs from AD brains were shown to contain all six
isoforms in a hyperphosphorylated state (84) and PHF-tau
contains 4–5-fold more phosphorylated residues than tau from
healthy control brains, taken by some to indicate an association
between hyperphosphorylation of tau with tau assembly in
AD (126, 127). In conjunction with this, higher levels of
extracellular hyperphosphorylated tau are measured in patients
with AD (128). Hyperphosphorylation of tau may drive some
disease-relevant features such as a lower binding affinity for
microtubules; reduced biological activity; mis-localization within
the cell; increased ability to aggregate into PHFs; and to
contribute to neuronal death (49, 129–138). It has been argued
that tau phosphorylation could be the trigger of its self-
assembly, with an increase in tau phosphorylation observed
prior to the formation of tau aggregates (139–143). On the
other hand, biochemical studies of tau accumulation in the
course of disease do not suggest the existence of a soluble
pool of free phosphorylated tau prior to aggregation (144), and
indeed the appearance of soluble forms of hyperphosphorylated
tau becomes measurable in the cortex only at advanced stages
of pathology (56). Other studies have suggested that it is
not the overall phosphorylation state of tau that may trigger
aggregation, but the phosphorylation of specific sites. Combined
phosphorylation of S202/T205/S208 sites in the AT8 epitope
(shown in Figure 1), with the lack of phosphorylation at S262,
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contributes to filament formation (145). In contrast, Zhou and
colleagues observed a dramatic increase in the phosphorylation
sites, including S262, in association with the formation of high
molecular weight oligomers of tau in AD brains (146). In
addition, Tepper and colleagues suggested that phosphorylation
of tau in cells promotes oligomer formation but not filaments
(147). Alternatively, phosphorylation may be secondary to
formation of oligomers and consequent mis-sorting of tau (110).
The involvement of tau phosphorylation in tau assembly is
supported by the observation that there is a 50% reduction in
the prominent phosphatase, PP2A, observed in AD brains (124).
Dephosphorylation of PHFs isolated from AD brains results in
their dissociation and disaggregation (148), as well as restoring
normal tau function to promote assembly of microtubules and
abolishing its pathological self-assembly (131, 149). These studies
support an association between hyperphosphorylated tau and
its self-assembly into PHFs. However, other groups have shown
conflicting results. Initial studies of the PHF core revealed
that, after Pronase treatment, PHFs were not recognized by
phosphorylation-dependent antibodies (74, 81). Other studies
have shown that only a minor proportion of PHF-tau is
either full-length or hyperphosphorylated (<5%) (150) and tau
species isolated from the proteolytically stable PHF-core are
not phosphorylated (151). This suggests that the sites of tau
phosphorylated in the PHFs are located only in the “fuzzy
coat” and are not structural components of the PHF-core. This
has been further supported by Arkhamia and colleagues, who
showed that phosphorylation occurs largely in the “fuzzy coat”
region of CBD and AD filaments using mass spectrometry (152).
Furthermore, the structural core revealed by cryo-EM comprises
regions downstream of key phosphorylation sites such as the AT8
epitope (153–155) (Figure 2). Additional studies have questioned
the role of phosphorylated tau in the mechanism of tau self-
assembly. Studies have implied that hyperphosphorylation of
tau inhibits tau-tau binding (109, 156), inhibits its aggregation
(157), and is not sufficient for filament propagation in cellular
models (158, 159).
Truncation
Tau is sensitive to proteolytic digestion that is facilitated by a
group of proteases. Tau is a substrate for a variety of proteases,
such as caspase (160), calpain (161), cathepsin (162), and
thrombin (163). As previously stated, initial studies identified
truncated tau as the structural component of the Pronase-
resistant PHF core (74, 81). Truncation of tau protein can act
as a driver of tau self-assembly in the process of autocatalytic
propagation by removal of occluding N- and C-terminal domains
of the molecule (Figure 3) (108, 110). As a natively unfolded
protein, tau has little tendency to aggregate in physiological
conditions (103). However, there is evidence that tau can change
its conformation into a “paperclip” loop, by folding its N- and
C-terminal regions back onto the microtubule-binding repeats,
thought to inhibit or protect against pathological aggregation
(164). Tau fragments truncated at both N- and C-termini that
contain the microtubule-binding repeats are more prone to form
aggregates, probably because the protective “paperclip” loop has
been disrupted (165). It has been suggested that truncated tau can
facilitate the assembly of full-length tau for fibril formation and is
the driving force behind NFT formation (47, 160, 166, 167). The
self-assembly of truncated tau observed with the in vitro model
dGAE form fibrils that structurally resemble PHFs in ADwithout
inducers (168, 169); dGAE is one of the PHF-core tau species
isolated from AD brain tissue (74, 84).
PHF-core tau isolated from Pronase-treated PHF preparations
from AD brain comprises a number of different fragments
encompassing residues 297–391 and 264–359 from the repeats
R2–R4 and repeats (R1–R3) of the 4-repeat isoform, and residues
266–391 of the 3-repeat isoform (74, 82, 83). The 296-390
fragment binds full-length 4-repeat tau with high affinity (156)
and generates the species terminating at E391 in vitro (108).
Tau C-terminally truncated at E391 is found in early amorphous
deposits in AD brain tissues and the epitope becomes occluded
as filaments form (170). Tau truncated at E391 was identified
in PHFs isolated from AD brains after-Pronase treatment using
mAb 423, which recognizes the C-terminal E391 in PHFs, but
not normal adult tau proteins (85, 171). The E391 truncation and
truncations at homologous positions in other isoforms, therefore
represent the proteolytically stable footprint of the high affinity
core-tau aggregation domain (82).
Tau truncated at D421 is produced by caspase activity, which
is elevated in AD brains (172, 173). It has been shown that
Aβ (1–16, 23–48) peptide exposure can trigger caspase cleavage
of tau to produce the N-terminal tau 1–421 fragment, which
assembles more readily into filaments than full-length tau. This
study suggests a possible link between Aβ, induction of tau
PTMs and the initiation of tau self-assembly into filaments
(160). In addition, studies have indicated that caspase-mediated
truncation of tau at D421 may precede hyperphosphorylation
and aggregate formation in AD, PiD and PSP, which may
be an important step in understanding tau self-assembly for
tauopathies (174–177). Studies have also demonstrated that tau
truncated at D421 may become an effector of apoptosis, further
linking pathological tau to neurodegeneration (178, 179).
On the other hand, an in vivo study using the P301S transgenic
mouse model demonstrated that hyperphosphorylation precedes
the truncation of tau at D421 and that truncation occurs after
filament formation (180). This suggests that this particular
truncation is not necessary for filament formation. Further
studies indicate that phosphorylation and N-terminal truncation,
but not C-terminal truncation, are more significant in the
formation of oligomeric tau species (146). This further
demonstrates the complexity of tau self-assembly and highlights
the gaps in our understanding of the initial steps in the formation
of aggregates. Identifying an in vitro model that can accurately
replicate the pathological processing of tau in AD brains will
greatly assist in studies on tau self-assembly, as well as other
important aspects of tau pathology, such as its propagation
throughout the brain.
Trans-cellular Propagation of Tau and
Seeding
If tau pathology were restricted to affected neurons, then the
damage induced by tau would be self-limiting. As discussed
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earlier, propagation of tau is thought to be through a prion-
like mechanism, which utilizes an initial seed to recruit normal
monomeric tau and is able to facilitate autocatalytic amplification
(110). The initial seed could be undigested cellular components,
such as lipofuscin deposits (109), or it could be tau in an
oligomeric state. Recent studies have supported the proposal that
tau itself can undergo active cell-to-cell (trans-cellular) transfer
and initiate the propagation of tau aggregates in previously
unaffected neurons, whereby it seeds further tau aggregation
(181, 182). Understanding the mechanism whereby pathological
tau can spread throughout the brain is a major focus for
dementia research and offers the potential of being an important
therapeutic target for attenuating the progression of tauopathies.
Initial studies observed the formation of intracellular tau
aggregates after tau was applied extracellularly, demonstrating
the ability of tau to seed assembly in adjacent cells in vitro
(183) and in vivo (184). It was further shown that intracellular
tau aggregates are released and taken-up by co-cultured
cells, whereby the internalized aggregates induced assembly
of intracellular tau and promoted fibrillization, demonstrating
prion-like propagation of tau (115, 181, 182). Additional
studies have shown that the trans-cellular propagation of
tau is facilitated by synaptic connections between neurons
(trans-synaptic propagation) that seems to be stimulated by
depolarization during neuronal activity, which can accelerate
the spread of tauopathy (185–191). The spread of tau through
trans-synaptic propagation via specifically connected neurons
may explain the stereotypical staging of tau pathology seen
in AD (192). However, the mechanisms that facilitate tau
intercellular propagation through secretion and uptake are not
fully understood. Several studies indicate that tau secretion is
enabled via vesicles known as exosomes (193–196) and ectosomes
(188). Microglial cells may also promote tau propagation through
exosome-dependent mechanisms (197). In contrast to these
findings, a study indicated the secretion of tau is an exosome-
independent process, requiring heat shock cognate 70, chaperone
DnaJ and synaptosomal associated protein 23 (198). The secreted
pathological tau is required to undergo cellular uptake to gain
entry into neighboring cells, which has been linked to multiple
cellular uptake mechanisms. These include receptor-mediated
endocytosis (199), dynamin-driven endocytosis (187), and actin-
dependent proteoglycan-mediated micropinocytosis (200).
In addition to the mechanisms that govern intercellular
propagation, it is becoming increasingly important to consider
the species of tau that is responsible for initiating seeding.
Proteolytically stable oligomers have been the mostly widely
documented species responsible for intercellular self-propagating
tau and have the greatest seeding activity for initiating the
self-assembly cascade of tau in unaffected brain regions (115,
183, 184, 187, 201). Recent work has shown that the dGAE
fragment in soluble form can be internalized into neuronal
cells and can recruit endogenous tau (202). There is also
some evidence for fibril-induced tau propagation (203, 204).
Nonetheless, oligomeric tau is still thought to be the key species
that gives tau pathology its “prion-like” characteristic.
Recognizing the self-propagating nature of tau and the seeding
abilities of different tau species in tauopathies has opened up
new possibilities for therapeutic targets and interventions for
the treatment of tauopathies. The anti-tau antibody infusions
and small molecules to disrupt the propagating mechanism
of tauopathies are attractive therapeutic strategies. These
therapeutic targets will be discussed later in the review.
Although NFTs are considered histopathological hallmarks
of AD, there is increasing evidence that the cytotoxicity
associated with tauopathies may not be as a result of these larger
aggregates. In addition to trans-cellular propagation, oligomers
are associated with the molecular dysfunctions that underlie
neurodegeneration and the cognitive decline seen in patients. In
vivo tau-overexpression studies have demonstrated neuronal loss,
behavioral abnormalities, and synaptic dysfunction occurring
in the absence of NFTs (205–212). These studies indicate a
pathological role for pre-tangle tau species in the dysfunction
of neurons. This has been further supported by evidence that
injection of tau oligomers into wild-type mice induces memory
impairment, synaptic loss, and mitochondrial dysfunction, that
are not seen with monomer or fibril injections (213). In addition,
following a decrease in oligomeric tau levels, improved cognitive
function suggests the potential of anti-tau antibody infusions as
a therapeutic approach (214). In response to these findings, it
has been proposed that mature tau fibrils could be a protective
response to absorb the more toxic oligomeric species, eventually
inducing their clearance via protease activity or autophagy
(215, 216). However, the oligomers formed through the repeat
domain are proteolytically stable and hence resist proteolytic
and autophagic activity, and are therefore able to propagate
between neurons and induce cytotoxicity. Tau-induced
neurodegeneration may be due to an increase in oligomers
rather than due to the accumulation of PHF in NFTs. This
concept has been proposed for other neurodegenerative diseases,
but still remains to be validated with respect to tau and AD (217).
Investigating the molecular mechanisms underlying
protein self-assembly has been an important focus for further
understanding of neurodegeneration and identifying therapeutic
targets. Generating a reliable in vitro model that can accurately
replicate the protein self-assembly and associated cytotoxicity
that occurs in tauopathies will further our understanding of
the underlying principles of aggregation and the potential for
therapeutic targets. However, it presents a huge challenge to
create an in vitromodel that will effectively replicate pathological
processing of tau that occurs in vivo, whilst also modeling other
aspects of interest, such as the production of representative
oligomeric species.
Models of Tau Aggregation
Brain-derived materials are inherently variable, and variations
are difficult to control. Hence, there is a need for an in vitro
system using synthetic tau that can recapitulate the pathological
self-assembly of tau observed in the brains of tauopathy patients.
Due to its hydrophilic nature, recombinant tau shows very little
tendency to aggregate, making it a difficult protein for study of its
aggregation and cytotoxicity mechanisms (102). Thus, multiple
tau models have been developed that exhibit a higher tendency to
aggregate and enable effective in vitro research. Here we discuss
some of these models, summarized in Figure 4.
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Full-Length Tau (T40, 2N4R)
The largest tau isoform, also known as full-length tau or
T40 (441 residues), incorporates both N-terminal inserts and
four microtubule-binding repeats (2N4R tau: Figure 4). The
full-length tau in vitro model will be referred to as T40
for this section of the review. This isoform has been used
extensively to study the role of tau in disease. Tagging T40
with diverse fluorescent proteins (GFP, YFP, and CFP) has
been a useful tool to visualize tau aggregation in vitro and
further our knowledge of tau assembly (153, 218). Frost and
colleagues used fluorescently tagged endogenously expressed T40
in their studies to demonstrate tau propagation and seeding,
as summarized earlier. They showed that tau-YFP does not
readily aggregate within the cell but, when they introduced
tau as a pre-assembled aggregate into the cell, it induced
fibrilization of the tau-YFP (183). Groups have been able to
develop cell-based models that can monitor and quantify tau
assembly by utilizing fluorescence resonance energy transfer and
biomolecular fluorescence complementation technology using
T40 (154). Using these techniques, groups were able to achieve
spatial and temporal resolution of tau aggregation in living cells
following hyperphosphorylation (219), and demonstrating the
role of GSK3β and caspase cleavage in intermolecular association
of tau (220, 221).
Many investigators have used T40, either as a monomer or
having induced filament assembly by the addition of cofactors,
such as heparin (104, 105, 155), RNA (106), or fatty acids
(107). T40 filaments resemble those found in AD brains. These
cofactors enhance tau aggregation by inducing a conformational
change from mostly random coil to β-sheet structure in the
microtubule-binding domain containing the hexapeptide motifs
thought to be necessary for assembly (87, 88, 222, 223). Heparin-
induced filaments have become an important tool used to study
pathological tau aggregation, such as investigating the effects of
MAPT mutations on tau assembly (224, 225) and investigating
potential aggregation inhibitors (226–228). They have provided
a platform to characterize the progressive fibrilization of
tau, through monomeric aggregation into intermediate species
and ultimately into filaments (229). In addition, heparin-
induced aggregates of T40 were used to support the role
of PHF6∗ hexapeptide (275VQIINK280) as a potent driver of
aggregation and seeding for full-length tau, suggesting that it
is a superior target for inhibition when compared to the PHF6
hexapeptide (112). Crespo and colleagues have used heparin-
induced filaments to produce an assay, which they claim to be
highly reproducible and closely mimicking in vivo tau misfolding
and aggregation (230). They suggest that the assay will enable
mechanistic studies on tau pathogenesis and can be utilized for
evaluating candidate drugs during screening processes.
These studies illustrate the importance of full-length tau as
a tool in understanding of both physiological and pathological
tau. However, T40 may not be a reliable model for AD research.
Evidence shows that heparin-induced tau has reduced seeding
activity compared to tau from the brains of mice expressing
human P301S tau (231). Additional studies have shown structural
differences in tau filaments seeded using tau from AD brains and
recombinant tau assembled with heparin (159). Recently, Fichou
and colleagues reported that heparin-induced tau filaments do
not reproduce the main structural features seen in filaments
from AD brains, such as the C-shape Alzheimer’s fold and
the anti-parallel β-sheet structure between 303–347 and 349–
378 (100). Moreover, cryo-EM revealed that heparin-induced
filaments of 4R (full-length) tau are polymorphic, adopting
at least four different conformations, with 3R tau adopting a
conformation of its own (232). All of these conformations are
structurally distinct, consisting of an ordered core structure,
which is very different to those characterized using cryo-EM
of filaments from AD, PiD, CTE, and CBD. The studies also
revealed that these filaments lack essential features of AD
PHFs, such as the interface between PHF6 and its opposing
residues 373–378. These findings indicate that heparin-induced
filaments of T40 tau are both structurally heterogeneous and
distinct from those found in the disease brain, challenging their
reliability for use in a tau self-assembly model or as an assay for
screening potential inhibitors. As noted above, heparin-induced
filaments from full-length tau were used as a basis for inferring
FIGURE 4 | Positioning of tau fragments used as models for studying tau biology showing full-length T40 in relation to the AD cryo-EM derived structure (shown in
red). dGAE covers I297—E391, incorporating a C-terminal portion of R2, R3, and R4 (shown in pink). The C-terminal E391, recognized by mAb 423, is absent in dGA,
a fragment ending in A390. K18 (Q244—E372) covers all four repeat domains; K19 covers the same region but lacks residues 275–305 (R2) encoded by exon 10 in
4R isoform.
Frontiers in Neurology | www.frontiersin.org 10 November 2020 | Volume 11 | Article 590754
Oakley et al. Exploring Tau Self-Assembly as a Therapeutic Target
the importance of PHF6∗ in assembly (112). Recent cryo-EM
structures of the heparin-induced filaments indicate that the
PHF6∗ region is located in the cryo-EM core of T40 filaments
forming a contiguous β-strand, whereas it not found within
the core of AD filaments. It is however visible within the core
of the recent cryo-EM structure for CBD filaments at the far
N-terminal end (residues 274–280), so it may yet be resolved
in more detailed PHF structures (Figure 2). This illustrates a
potential disadvantage of the heparin-induced T40 model for
investigating tau self-assembly. This model produces filament
structures that are distinct from those so far characterized from
tauopathies andmay have a different mechanism of self-assembly
and highlighting factors that are not applicable for tauopathies.
Nevertheless, it is important to consider what we can learn
from these heparin-induced filaments. Even though there are
structural differences between such filaments and tauopathy
filaments, they do exhibit similarities. They are composed of tau
molecules that form cross-β structures through parallel stacking
of β-strands along the helical axis. The β-strands contain short
loop regions and the filament structures share a common pattern
of β-strand formation (232). Studying the formation of these
filaments may shed light on key assembly processes, or they
could be more relevant for other tauopathy filaments that have
not been solved yet, such as PSP. In addition, cofactor-induced
aggregates spontaneously disassemble into monomers when the
cofactor is removed (233). The authors of these studies have
proposed that unknown cofactors may play a role in tau self-
assembly in tauopathies and these could provide a potential
therapeutic target.
Overall, T40 has been used extensively to model tau assembly.
It has been extremely useful in uncovering the role of tau,
both physiologically and in pathology. The use of heparin
to induce aggregation of tau into filaments that may have
some resemblance to disease-like filaments has made it an
attractive model when investigating tau self-assembly. Given
the recent evidence of structural dissimilarities from native
filaments, T40 heparin-induced filaments should be used with
caution in structure-based studies for drug design and antibody
development, where structural accuracy is essential. This does not
preclude the use of T40 in assembly assays, but rather reveals
that the unique structures of heparin-induced T40 filaments
differ from the pathologic filaments. The use of full-length
tau in the generation of filaments should still be open to
further investigation, using a range of biophysical techniques to
determine the mechanism of initiation of aggregation. Future
research may unveil a novel mechanism for induction of
aggregation of T40 which may make it a more suitable candidate
for the investigation of tau self-assembly.
Repeat Domain Models (K18/K19)
Since the microtubule-binding repeats domain were shown to
compose the core region of PHFs and facilitate the pathological
tau-tau binding (74), it has been common practice to use
tau fragments that only comprise of the microtubule-binding
domain. Some groups simply refer to them as the microtubule-
binding region (MTBR) and specify whether they use the 3R
or 4R isoforms. Others use two model peptides, termed K18
and K19. K18 represents all four-repeat domain and contains
residues 244–372, while K19 is similar to K18 but lacks the
second repeat (missing residues 275–305) absent from 3R
tau isoforms (Figure 4) (234, 235). As stated previously, tau
fragments including MTBR and truncated at both N- and C-
termini are more prone to form aggregates than full-length tau
(165) and aggregation can be further stimulated by including
mutations or adding cofactors, such as heparin (102, 236). They
produce filaments that resemble AD PHFs in terms of fiber
morphology and β-sheet content (87, 88, 227), which provided
the basis for using MTBR in tau assembly studies.
As mentioned previously, the Diamond group have used full-
length tau in their study on the propagation and seeding of
tau (183). The full-length tau did not aggregate spontaneously
in cells, so they utilized a MTBR fragment similar to K18,
corresponding to residues 243–375. They were able to prepare
in vitro aggregates of the MTBR fragment with arachidonic
acid, which readily entered cells and induced aggregation of
intracellular T40-YFP. This demonstrated that T40 does not
readily aggregate in cells, but internalized MTBR aggregates
were able to induce fibrilization of the intracellular T40-YFP.
These studies also used the expression of mutant forms of the
MTBR models to further our understanding of tau propagation.
Multiple K18 mutants, labeled with YFP or CFP, were used to
demonstrate that the secretion of fibrils into the extracellular
space leads to the internalization of these fibrils by other cells
and the aggregation of the intracellular tau, supporting the
concept of trans-cellular propagation of tau aggregates (181). The
authors advocate the use of the K18 construct on the grounds
that it reliably forms fibrils in cultured cells and aggregation
potential can be modulated with the introduction of specific
mutations. This includes the combined P301L and V337M
mutant (termed LM), enabling efficient formation of intracellular
aggregates and providing an effective model of tau propagation.
In addition, the expression of the aggregation-competent MTBD
fused to YFP was utilized to confirm the prion-like nature of
tau (182). Similar to T40, filaments can be prepared using K18
and K19 with the addition of cofactors. The Mandelkow group
have used the heparin-induced aggregation of K19 extensively
as a model in investigating inhibitors of tau polymerization.
They have utilized the K19 model to screen a library of
200,000 compounds in the search for potential inhibitors of tau
aggregation, and therefore potential therapeutic agents. They
were able to identify rhodamines, phenylthiazolyl-hydrazides,
N-phenylamines, anthraquinones and benzothiazoles (237–239)
and aminothienopyridazines as a novel class of tau assembly
inhibitors (240, 241). They also utilized the K18 and K19
fragments to identify the hexapeptide motifs considered to be
essential for tau aggregation, PHF6 and PHF6∗ (87, 88).
Although these studies have proved informative in tau self-
assembly studies, it is now possible to compare filaments
composed of K18 and K19, with genuine filaments isolated from
AD brains. The cryo-EM of PHFs has shown that the N-terminal
cross-β structure is formed by the PHF6 hexapeptide, which is
essential for assembly of tau (87, 88) (Figure 2). PHF6 packs
against its opposing residues 373–378, which are not present
in the K18 and K19 fragment because they terminate at E372
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(62, 234). Thus, filaments composed of K18 and K19 fragments
cannot be said to reproduce the Alzheimer’s fold resolved in
PHFs and SFs derived from AD brains. In addition, since K18
and K19 terminate at E372, these fragments lack the C-terminus
after the MTBR, that has been shown to contribute to the core
region of filaments seen in AD, PiD, CTE, and CBD (in AD
this extends to residues 378, in PiD to 378, in CTE to 379, and
in CBD to 380), which casts further doubt on the use of such
filaments as models for assembly assays. As stated previously,
the use of heparin to induce K18 and K19 filaments must be
used with caution, as it has been shown that heparin-induced
filaments are highly heterogenous and differ from those seen in
tauopathies (232).
dGAE Model
dGAE is a 95 amino acid truncated form of tau protein
corresponding to residues 297–391 encompassing part of R2,
and R3 and R4 from full-length 2N4R tau (Figures 2, 4). The
fragment corresponds to one of the species isolated from the
proteolytically stable AD PHF core preparations (74, 82, 84). The
terminology of dGAE refers to the three C-terminal residues,
glycine (G), alanine (A), and terminating with glutamate (E),
E391; the initial letter corresponds to the N-terminal residue
which for “d” refers to I297 (82). Tau truncated at E391 was
identified as being part of the Pronase-resistant core during
initial proteolytic and antibody studies, which is recognized by
mAb 423 (Figure 2). PHFs isolated from AD brain without
Pronase are also recognized by mAb 423, but require a higher
concentration of antibody (82). mAb 423 immunoreactivity can
also be revealed in intracellular tangles following treatment
with formic acid in dystrophic neurites and in granulovacuolar
degeneration in AD brain sections (170, 242, 243) supporting the
view that C-terminal truncation at E391 is not a Pronase artifact.
Rather, digestion by endogenous proteases may be one of the
events leading to PHF formation and depends on a particular
configuration of tau found in partially assembled precursors,
and also in fully assembled PHFs. The dGAE peptide and
other core peptides were proposed as representing an integral
part of the stable core region in PHFs (82, 108, 170, 244,
245) and has now been confirmed as encompassing slightly
shorter PHF ordered core region (304–380) resolved using
cryo-EM (62) (Figure 2).
dGAE was chosen for further study because it is also similar
to repeats R1/R3/R4 from the 3-repeat isoform apart from 3
residues near the N-terminus (L/I, Q/V, K/S in the 3-repeat
and 4-repeat isoforms, respectively) and is therefore likely to
be representative of the behavior of both isoforms (Figure 2).
Studies of the assembly properties of the dGAE peptide has
revealed that it has the ability to self-assemble spontaneously
in physiological conditions in vitro, without the need for added
cofactors, such as heparin. Self-assembled dGAE filaments have
been shown to share characteristics of amyloid fibrils, displaying
β-rich structure and giving a cross-β X-ray fiber diffraction
pattern (168), as well as closely resembling PHFs in AD brains
(169). Transmission electron microscopy revealed no significant
variations between dGAE filaments and no significant variations
between dGAE filaments and AD filaments. Atomic force
microscopy also demonstrated that dGAE forms filaments that
share macromolecular characteristics with PHFs fromAD brains.
These results suggest that dGAE functions as a consistent and
reliable model for understanding pathological tau self-assembly
and for screening inhibitors and understanding their mode
of action.
Disulphide crosslinking between dimers was proposed to be
an essential part of tau assembly and propagation (102, 246–248).
Disulphide cross-linkages are formed between cysteine residues,
located on tau at C291 and C322 (numbering for 2N4R tau), in
which C322 exists in all tau isoforms, whereas C291 is only found
in 4R tau isoforms. The assembly of filaments from dGAE was
found to be enhanced in conditions unfavorable for disulphide
crosslinking formation and with a variant lacking the cysteine
residue all together, dGAE-C322A (168). The authors concluded
that assembly of dGAE is independent of disulphide crosslinking
and suggested that the formation of disulphide bonds competes
with crucial conformations required for filament formation. This
is at odds with previous suggestions that disulphide-linked dimer
formation is an important step in filament formation, but is
consistent with the structure of ex vivo PHFs by cryo-EM (62).
This shows that the C322 residue is buried between sheets
and would be inaccessible for disulphide crosslinking (62, 168)
(Figure 2). This evidence suggests that dGAE provides a more
accurate representation of pathological tau in AD, in comparison
to the models used in previous studies (1N3R, 1N4R, and K18),
which require exogenous heparin for assembly. In addition,
Al-Hilaly and colleagues identified two monomeric isoforms of
dGAE, one with a gel mobility of 10 kDa and the second with
a mobility of 12 kD. The same doublet was seen in the proteins
extracted from the core region of PHFs isolated from AD brain
tissue, which first lead to the identification of truncated tau as a
structural component of the PHF cores (74, 168).
The dGAE fragment has also been utilized for the
investigation of tau aggregation inhibitors (TAI). dGAE, and a
fragment similar to dGAE but lacking the E391 residue (dGA),
were used in the study which identified the methylthioninium
(MT) moiety as the first TAI (108). Since then, other groups
have attempted to understand the mechanisms of MT action
by using heparin-induced filaments composed of the MTBR
fragments, K18 and K19 (249, 250). These studies hypothesized
that the TAI activity of MT requires cysteine oxidation, which
was consistent with the previous proposals stating that tau
assembly was dependent on disulphide crosslinking. However,
a recent study using the dGAE fragment has shown that MT
acts optimally as a TAI in its reduced form as leuco-MT (LMT)
rather than the oxidized form at MT+ (251). The evidence that
LMT is the active form of MT required to inhibit pathological
aggregation of tau is at odds with the proposal that its action
depends on the oxidation of cysteine residues (249, 250). The
ability of LMT to act as a TAI is also consistent with an earlier
study showing that dGAE assembly into PHFs is independent
of disulphide crosslinking. In addition, circular dichroism has
revealed that heparin interacts with MT. This confounds studies
aiming to understand how LMT acts, and further supports the
use of dGAE for such studies (251). LMT will be discussed in
more detail later in the review.
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We can only compare dGAE and AD filaments directly once a
structure has been resolved for dGAE through the use of cryo-
EM or solid-state nuclear magnetic resonance. As previously
mentioned, the filaments seen in CTE share similar morphology
with AD filaments, but cryo-EM revealed subtle ultrastructural
differences, which could be the case for dGAE filaments and
PHFs. However, the studies to date highlight the use of dGAE
as a reliable in vitromodel able to replicate tau self-assembly in a
controllable manner. It may therefore prove to have broader use
as a relevant tool for the investigation of assembly mechanisms
and the potential therapeutic targets.
ALZHEIMER’S DISEASE THERAPIES
TARGETING TAU SELF-ASSEMBLY
The clear involvement of tau self-assembly as a driving force
behind the clinical progression of AD, as well as other
tauopathies, has established it as an attractive target for potential
therapies. Treatments for AD are extremely limited and offer
only temporary symptomatic relief based on neurotransmitter
enhancement, without providing disease-modifying activity.
Extensive clinical studies have resulted in over 400 failed trials
since the last AD treatment was approved in 2003 (47, 252).
Targeting tau self-assembly to reduce disease progression has
resulted in promising results and may provide much-needed
disease-modifying treatment options for AD. Here we discuss
some of the treatment options targeting tau self-assembly in AD,
utilizing small molecule and immunotherapy approaches.
Tau Aggregation Inhibitors (TAI)
Low molecular weight compounds offer a promising approach
for inhibiting the formation of oligomers and fibrils by blocking
tau-tau interactions. The microtubule-binding domains have
been shown to be responsible for the pathological tau-tau
binding, but also facilitating the tau-tubulin binding required
for physiological tau function (27, 108). Thus, TAIs should
inhibit pathological tau-tau binding whilst not affecting the
physiological tau-tubulin interaction, although both occur
through the repeat domain. Potential side-effects are extremely
important to consider for compounds destined for clinical
trials. Wischik and colleagues demonstrated the first TAI to
be MT, a diaminophenothiazine. Since then, other compounds
have been shown to exhibit TAI activity, such as the potential
TAIs identified by the Mandelkow research group, mentioned
previously (237–239). None of these potential TAIs have yet
reached clinical testing. Both the oxidized MT+ and reduced
LMT forms of MT have shown promising results in Phase 2 and
Phase 3 clinical trials, respectively.
Methylthioninium chloride (MTC, commonly known as
methylene blue) was originally synthesized at the end of the
nineteenth century for the treatment of malaria, and since then
has had a long history of clinical applications. Importantly for
AD research, Wischik and colleagues reported MTC as the first
TAI, demonstrating its ability to reverse the proteolytic stability
of PHFs isolated from AD brain and selectively inhibiting tau
self-assembly, without affecting normal tau-tubulin interactions
(108). Additional in vitro and in vivo studies have confirmed
MTC as an effective TAI (245, 251, 253). As noted above,
it is actually the LMT form which is the active species
responsible for TAI activity in the dGAE model of pathological
tau assembly. Other studies have suggested that MTC induces
degradation of tau aggregates by promoting the proteasomal
(254) and macroautophagic (255, 256) clearance systems.
The MT moiety has also shown potential for ameliorating
mitochondrial dysfunction and reducing oxidative stress, by
acting as an alternative electron carrier for the electron transport
chain in oxidative phosphorylation (257–264). In vivo studies
have confirmed that both MTC and a stabilized form of LMT
[LMTM, leuco-methylthioninium bis(hydromethanesulfonate)]
are able to preserve cognitive function and reducing behavioral
deficits associated with pathological tau aggregation in tau
transgenic mouse models (253, 265, 266). In cell models, LMTM
was shown to block the templated conversion of full-length
tau into the truncated 12 kDa form analogous to dGAE (245).
Likewise, the tau species used in the Melis and colleagues
study to produce tau aggregation pathology in mice depends
on the overexpression of a truncated form of tau analogous to
dGAE (253).
The pharmacology of MTC is complex, existing as a redox
molecule in equilibrium between its reduced LMT form and its
oxidized MT species and dependent on the local environment
(253). Because its redox potential is close to zero the MT
moiety is able to act as an electron carrier between Complex II
and Complex IV in the electron transport chain, permitting it
to enhance mitochondrial function (257, 267). However, when
administered as MTC, the MT moiety needs to be reduced
to its uncharged LMT form to permit efficient absorption and
distribution to the brain (265). As noted above, MTC is optimally
effective as a TAI when converted to LMT in a reducing
environment, implying that LMT is the active species required
for inhibition of tau aggregation (251). Optimizing the clinical
effectiveness of LMT has been a challenge in clinical trials. The
MT moiety was first tested clinically in a pure, oxidized MTC
form under the name RemberTM (TauRx Theraputics) in Phase
2 clinical trial in mild-to-moderate AD. This showed significant
efficacy compared with placebo in terms of reduction in cognitive
decline and prevention of decline in brain metabolism as shown
by HMPAO-SPECT scan which measures cerebral blood flow
(268). However, MTC was found to suffer from dose-linked
absorption limitations (268) arising from the need for the body
to convert MT+ to the active LMT form required for efficient
absorption and distribution to the brain (265). A stabilized
form of the reduced LMT was developed which permits direct
administration of LMT as the mesylate salt, LMTM. LMT has
recently been assigned the International Nonproprietary Name
“hydromethylthionine.” LMTM retains TAI activity in vitro
and in vivo (245, 253), whilst exhibiting superior pharmaceutic
properties (265). Results from Phase 3 trials with LMTM have
shown promising results with exposure-dependent reduction in
cognitive decline and progression of brain atrophy as measured
by MRI. LMTM was found to produce better outcomes when
given as a monotherapy than as an add-on to symptomatic AD
treatments (269, 270). However, a recent report has demonstrated
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that there is similar exposure-dependent activity whether LMTM
is administered as a monotherapy or as an add-on, but that the
overall effect was reduced by about half as add-on (271). This
impairment in the activity of LMTM by symptomatic AD drugs
could be reproduced in a tau transgenic mouse model for AD,
and was found to depend on the brain’s homeostatic responses
to the activating affects that symptomatic drugs depend on for
their ability to boost cognitive function temporarily (267). The
concentration-dependent effects showed that LMTM requires a
substantially lower dose for pharmacological activity than found
for MTC (271). Currently, TauRx is undertaking a new clinical
trial (LUCIDITY) which aims to confirm the treatment effects
of LMTM on cognitive decline and brain atrophy in mild-to-
moderate AD.
Interestingly, LMTM was found to have an almost identical
exposure-response profile in a large Phase 3 clinical trial of
bvFTD as that seen for AD (272). Fewer than half of bvFTD
patients have tau aggregation pathology, with the remainder
exhibiting pathological aggregation of TARDNA binding protein
43, TDP-43. LMTM was found to have activity in mouse
model of FTD expressing full-length human tau carrying
mutations at P301S and G335D (253). The fact that LMTM
has similar pharmacological activity in both AD and bvFTD
raises the possibility that the subtle folding differences in the
tau filament core in the two diseases may not be important for
pharmacological activity for this drug. There is as yet no in vitro
model for Pick-like tau aggregation as distinct from AD-like tau
aggregation to permit examination of this question. However,
this example illustrates again the importance of developing
reliable and reproducible models that can be used to study
distinct mechanisms of aggregation and activity of TAIs.
Curcumin is another compound that has been reported to
exhibit TAI properties. Curcumin is a natural polyphenol isolated
from the Indian spice turmeric, which has been reported to
inhibit assembly of tau (273–275) and Aβ (276). However,
curcumin has poor bioavailability and had no effect on cognition
or cerebrospinal fluid biomarkers in a Phase 2 trial (277, 278).
Therefore, a derivative of curcumin, PE859, has been synthesized
that exhibits higher inhibitory activity against tau and Aβ
assembly in vitro, with high absorption and penetration of the
blood brain barrier. Oral administration of PE859 delays onset
and progression of motor dysfunction in JNPL3 human P301L
tau transgenic mouse (279). Further investigation illustrated the
effects of PE859 in vivo, demonstrating its dual aggregation
inhibitory activity and ameliorating cognitive dysfunction in the
senescence-accelerated mouse prone 8 (SAMP8), which show
age-related deficits in memory and learning (280). Okuda and
colleagues were also able to show that PE859 is protective with
respect to Aβ-cytotoxicity in vitro. The potential for combined
anti-aggregation activity for tau and Aβ makes PE895 an
attractive candidate for clinical trials.
Immunotherapy
The potential use of immunotherapy to combat protein self-
assembly was initially recognized with studies using antibodies
targeting Aβ peptide, which resulted in attenuating Aβ
pathology through preventing aggregation and removing existing
aggregates (281, 282). The use of successful immunization,
passive and active, against pathological tau was first reported
using an antibody targeting phospho-tau peptide encompassing
the pS396/404 epitope. The passive and active use of this
antibody therapy reduced pathological tau levels in mouse
models, while attenuating behavioral phenotypes associated with
tauopathies (283–285). In addition, the potential of an antibody-
based therapy for tau pathology was investigated by Kfoury and
colleagues who used amonoclonal antibody against the tau repeat
domain, HJ9.3 (epitope 306–321), to inhibit the trans-cellular
propagation of tau aggregation (181). Research has continued to
investigate the use of antibody therapies to inhibit tau assembly
and propagation, which has led to the inclusion of active and
passive immunizations in clinical trials.
Active
Active immunization induces the host immune system to
stimulate an antibody response and produces an immunological
memory with a long-lasting effect (47). However, eliciting
an immune response to a native protein poses the risk of
adverse immune reactions, which may affect normal tau and its
physiological functions (278). Active immunotherapy has been
shown to be effective in reducing pathological tau assembly and
the production of pathological tau aggregates (17–19, 283, 286,
287). AADvac1 is an active vaccine in clinical trials consisting
of a synthetic peptide derived from amino acids tau 294–305
coupled to keyhole limpet hemocyanin with an N-terminal
cysteine (19). It originated from in vitro studies of monoclonal
antibody DC8E8, which binds to a 6 amino acid sequence motif
(HXPGGG) present four times within the MTBR, preventing tau
oligomerization (20). Transgenic tauopathy rat studies showed
that immunization induced tau antibodies that bind to tau in
the brain, reduced tau pathology and ameliorated behavioral
deficits (19). Phase 1 trials of AADvac1 showed that 29 of 30
patients developed an immunoglobulin G response to the tau
peptide component of AADvac1 and against pathological tau
151–391/4R. Two patients withdrew due to adverse events, one
from a viral infection that lead to a seizure, thought to be due
to the vaccine, and the other an episode of microhemorrhage in a
patient with a history of this condition (21). The immunogenicity
of AADvac1 has prompted a larger phase 2 trial, which
is underway to further assess its safety and effectiveness in
alleviating clinical symptoms, and its effect on AD biomarkers
in the blood and CNS (278).
Passive
In passive immunization, monoclonal antibodies or immune
serum are administered directly to subjects. This tends to offer
a more transient effect than active immunization, but can be
useful in minimizing risks associated with active immunization
(278). The use of passive immunization has been shown not to
be limited to targeting extracellular tau. Studies have shown that
anti-tau antibodies are able to penetrate the blood brain barrier
and also to enter neurons, where they can target intracellular
pathological tau and tau aggregates (17, 22, 283, 288–290).
Having seen promising results with passive immunization, a
number of vaccines targeting various tau epitopes are being
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developed. BIIB092 (also known as BMS-986168) is a vaccine
currently focused as a PSP treatment, rather than AD. It targets
an N-terminal fragment present in extracellular tau (eTau) which
was originally observed to be secreted from neurons derived from
stem cells of familial AD patients (291). Bright and colleagues
showed a correlation between eTau and Aβ in vitro and in
vivo, whereby addition of eTau induced hyperactivity of neurons
and increased Aβ production, whereas targeting eTau with an
antibody recognizing residues 9–18 of eTau blocked these effects.
Two phase 1 trials were completed in patients with PSP and
healthy individuals and there is now a Phase 2 trial consisting
of 400 patients with PSP. RG7345 is a humanized antibody
that targets a specific tau phosphorylated epitope at S422 that
has been found enter neurons and reduce tau pathology in
transgenic mice (289). However, after a Phase 1 trial it was
discontinued by its developer (Biogen), presumably due to an
unfavorable pharmacokinetic profile, as it was showing a good
safety profile (278).
DISCUSSION
The inability of recombinant full-length tau to self-assemble
has limited its experimental use and has created a considerable
challenge in tauopathy research. To overcome this problem,
research groups have developed different in vitro tau models
in the hope of replicating the pathological aggregation of tau
observed in tauopathies. However, this has produced a number
of inconsistent findings, such as the contribution of PTMs to
assembly propensity and the importance of intrinsic tau features
in the assembly process. This illustrates the problem of the lack
of a general in vitro tau model tau self-assembly. The recent cryo-
EM studies revealing the structures core of filaments associated
with tauopathies have further highlighted the complexity of
tau self-assembly and the challenge in developing a reliable in
vitro tau model. Development of a generally agreed model that
consistently produces a reliable representation of pathological tau
aggregation will aid in identifying and understanding the key
features and mechanisms involved in tau self-assembly. This is
essential for identifying therapeutic targets for the development
of effective disease-modifying treatments.
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